1. Home
  2. MGF vs BMEA Comparison

MGF vs BMEA Comparison

Compare MGF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGF
  • BMEA
  • Stock Information
  • Founded
  • MGF 1987
  • BMEA 2017
  • Country
  • MGF United States
  • BMEA United States
  • Employees
  • MGF N/A
  • BMEA N/A
  • Industry
  • MGF Trusts Except Educational Religious and Charitable
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGF Finance
  • BMEA Health Care
  • Exchange
  • MGF Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • MGF 101.0M
  • BMEA 96.9M
  • IPO Year
  • MGF N/A
  • BMEA 2021
  • Fundamental
  • Price
  • MGF $3.08
  • BMEA $1.36
  • Analyst Decision
  • MGF
  • BMEA Strong Buy
  • Analyst Count
  • MGF 0
  • BMEA 7
  • Target Price
  • MGF N/A
  • BMEA $8.71
  • AVG Volume (30 Days)
  • MGF 104.4K
  • BMEA 1.6M
  • Earning Date
  • MGF 01-01-0001
  • BMEA 11-04-2025
  • Dividend Yield
  • MGF 7.64%
  • BMEA N/A
  • EPS Growth
  • MGF N/A
  • BMEA N/A
  • EPS
  • MGF N/A
  • BMEA N/A
  • Revenue
  • MGF N/A
  • BMEA N/A
  • Revenue This Year
  • MGF N/A
  • BMEA N/A
  • Revenue Next Year
  • MGF N/A
  • BMEA N/A
  • P/E Ratio
  • MGF N/A
  • BMEA N/A
  • Revenue Growth
  • MGF N/A
  • BMEA N/A
  • 52 Week Low
  • MGF $2.91
  • BMEA $1.22
  • 52 Week High
  • MGF $3.46
  • BMEA $8.28
  • Technical
  • Relative Strength Index (RSI)
  • MGF 52.92
  • BMEA 41.62
  • Support Level
  • MGF $3.05
  • BMEA $1.24
  • Resistance Level
  • MGF $3.10
  • BMEA $1.35
  • Average True Range (ATR)
  • MGF 0.03
  • BMEA 0.09
  • MACD
  • MGF 0.00
  • BMEA 0.02
  • Stochastic Oscillator
  • MGF 78.57
  • BMEA 49.91

About MGF MFS Government Markets Income Trust

MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: